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Intravenous estrogen is not proven
effective for abnormal uterine bleeding: 
guidelines are based on flawed evidence
STEPHEN SIMMER, B.A., Wayne State University School of Medicine, Detroit, MI, 
 
ABSTRACT A clinical appraisal and clinical application of: DeVore GR, Owens O, Kase N. 
treatment of dysfunctional uterine bleeding--a double
 
This appraisal identifies significant statistical irregularities in the study. A reworking of the study's statistics lea
different from that put forth by the authors of this paper: intravenous estrogen therapy is not, in fact, significantly more 
compared to placebo therapy for the cessation of acute abnormal uterine bleeding.
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Clinical Context 
A 48-year-old female patient presented to the emergency department for acute abnormal uterine bleeding (AUB). 
She had been bleeding profusely from her
was experiencing lightheadedness, dizziness, and fatigue. Labs revealed a hemoglobin of 5.9 mg/dL. Attempts to 
stop the bleeding with megace (40 mg QID) were unsuccessful; the next day, 
given, and the bleeding stopped.  
The use of IV estrogen to control this patient's bleeding was surprising to me. Prior to this case, I had thought 
progesterone to be the preferred treatment; it was my understanding tha
endometrium by halting proliferation and promoting differentiation, allowing for withdrawal bleeding upon its 
removal.
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Clinical Question 
Is intravenous Premarin
® 
(Conjugated Estrogen) effective in the cessation of acute 
Research Article 
DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding
randomized control study. Obstet Gynecol. 1982 Mar;59(3):285
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, intravenous estrogen, conjugated estrogen
 vagina for six days. The blood had soaked through her pants, and she 
IV estrogen (25 mg in 0.9% NaCl) was 
t progesterone would stabilize the 
abnormal uterine bleeding?
-91. 
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Literature Review 
Readily available secondary sources, including an 
Gynecologists
 (3,4)
, communicate that IV estrogen use is a mainstay medical treatment for acute AUB and reference the study by 
DeVore, et al. as sole evidence. Munro, et al. show
compared the use of medroxyprogesterone acetate and combination oral contraceptive pills.
effectiveness for both modalities, but not a clinically significant difference between the two.
article would be the only study to evaluate IV estrogen therapy for acute AUB; according to 
currently cited in 131 articles. This critical appraisal, therefore, looks at
modality and its effectiveness in this case scenario.
Critical Appraisal 
This is a randomized, placebo-controlled, double
Level 1b evidence according to the Oxford Centre for Evidence Based Medicine. The study was ‘partially open’ at the time it w
conducted, meaning that if bleeding continued after
regardless of which arm of the study the patient was assigned. This protocol was enacted due to the Human Investigation 
Committee’s belief—based on common practice at the time
patients in the control group.  
The strengths of this study lie in its research methods: randomized, placebo
subjects used in this study, the investigators performed both a Chi
Although the authors claim to use an intention-to
manner throughout the paper, and statistical significance is only the result of the authors' failure to assess the data in accordance 
with the intent-to-treat standard. At the onset of the study, 16 patients were assigned to the placebo group; however, following the 
first injections, two of these patients withdrew from the study entirely with no follow
significance by categorizing the two placebo patients as treatment failures. This is not in line with intent
state that once a subject is randomized into a treatment group, they cannot be removed when analyzed even if they withdraw fr
the study or are lost to follow-up.
7
  
The study also states that bleeding had stopped after two treatments in 72% of 
(p-value = 0.021). In order to obtain the 38% placebo response, the authors included the two dropout patients as treatment failu
However, assuming the two placebo group patients who withdrew had cessat
placebo arm would have responded. If this were the case, 50% of subjects receiving placebo would have stopped bleeding versus
72% in the treatment group. Using these new values, a Chi
IV estrogen group and the placebo group (p-value = 0.183) in stopping AUB. This does not prove that IV estrogen is ineffective; in 
this study, the authors simply fail to demonstrate that IV estrogen 
An appropriate critical analysis of this study should include a number needed to treat to determine the realistic value of th
medication to a patient. However, in this case a number needed to treat 
difference demonstrated between treatment and placebo groups. 
Note: This study was funded by a grant by Ayerst Laboratories, the same laboratory that manufactures 
 
Clinical Application 
The authors of this article skewed their results by assuming that two placebo patients who withdrew and were lost 
to follow-up would maintain their uterine bleeding. 
that even published authors misrepresent t
quality evidence; and third, that following guidelines alone is not the same as evidence
therapy is not without risks, most notably the increased chance of thrombotic
report, a patient died due to a saddle embolus after six doses of 25 mg of IV estrogen.
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April 2013 Committee Opinion from the American College of Obstetricians and 
ed evidence for high dose medroxyprogesterone acetate
(5,6)
 This latter study showed 
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 It is surprising that
Google Scholar
 the quality of evidence supporting the use of this treatment 
 
-blind study. It incorporates an open-label follow-up, demonstrating what should be 
 two cycles of injections, IV estrogen was administered on an open
—that IV estrogen was beneficial and should not be withheld from those 
-controlled, and double-blind. Considering the number of 
-square test and a Fisher’s exact test for statistical analysis. 
-treat analysis, the number of cases in each group is reported in an inconsistent 
-up assessment. The study calculates statistical 
the IV estrogen group and 38% of the placebo group 
ion of bleeding, eight out of the 16 patients in the 
-Square analysis shows that there is no statistical significance between the 
stops AUB more effectively than placebo.
cannot be calculated, because there is no absolute risk 
 
Premarin
Three lessons can be learned from this critical appraisal
heir own data; second, that current guidelines are based on poor 
-based practice. Estrogen 
 events. For example, in one case 
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The patient I encountered in the emergency department had symptomatic AUB that was refractory to 
progesterone therapy. One potential explanation for the clinical course of this patient is that she received 
progesterone followed by estrogen, which the attending physician may have thought to be the clinical equivalent 
of combination oral contraceptives. Currently, combination oral contrac
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